ALNY vs BBIO: stock comparison and AI forecast
Alnylam Pharmaceuticals, Inc. (ALNY) and Bridgebio Pharma, Inc. (BBIO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ALNY Alnylam Pharmaceuticals, Inc.
- Market Cap
- $21.42B
- P/E Ratio
- 7.5x
- Size
- large-cap
- AI Forecast
BBIO Bridgebio Pharma, Inc.
- Price
- $74.03 +7.6% · 6M
- Market Cap
- $14.42B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ALNY is 1.5 times larger than BBIO by market capitalization ($21.42B against $14.42B).
- ALNY turns 44.2% of its revenue into net income, against -59.8% for BBIO.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ALNY | BBIO |
|---|---|---|
| Market Cap | $21.42B | $14.42B |
| P/E Ratio | 7.52x | – |
| P/B Ratio | 5.94x | – |
| EPS | $21.27 | $-3.92 |
| Book Value/Share | $26.91 | – |
| Revenue/Share | – | $4.85 |
| FCF/Share | – | $-1.90 |
Profitability & Margins
| Metric | ALNY | BBIO |
|---|---|---|
| ROE | 76.8% | – |
| ROA | 34.6% | -26.2% |
| ROIC | 22.7% | -30.8% |
| Gross Margin | 78.7% | 94.3% |
| Operating Margin | 21.5% | -38.5% |
| Net Margin | 44.2% | -59.8% |
| EBT Margin | 17.5% | -67.9% |
| Tax Rate | -174.3% | 0.1% |
Financial Health
| Metric | ALNY | BBIO |
|---|---|---|
| Current Ratio | 2.48x | 2.09x |
| Quick Ratio | 2.43x | 2.03x |
| D/E Ratio | 1.22x | – |
| Financial Leverage | 2.22x | – |
| Interest Coverage | 4.7x | -0.3x |
| Working Capital | $3.05B | $1.07B |
Cash Flow
| Metric | ALNY | BBIO |
|---|---|---|
| Operating Cash Flow | $1.23B | -$369M |
| Free Cash Flow | – | -$370M |
| Capital Spending | – | -$830K |
| FCF/Sales | – | -39.1% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | ALNY | BBIO |
|---|---|---|
| Asset Turnover | – | 0.44x |
| Receivables Turnover | – | 2.5x |
| Inventory Turnover | 12.6x | 0.9x |
| Fixed Assets Turnover | – | 187.5x |
| Days Sales Outstanding | – | 145 days |
| Days Inventory | 29 days | 407 days |
| Payables Period | 37 days | 602 days |
| Cash Conversion Cycle | – | -50 days |
Income Statement
| Metric | ALNY | BBIO |
|---|---|---|
| Total Revenue | – | $946M |
| Operating Income | $1.35B | -$364M |
| Net Income | $2.77B | -$566M |
| R&D Expense | $1.92B | $536M |
| SG&A Expense | $1.66B | $709M |
| Cost of Goods Sold | $1.33B | $54M |
Dividend & Shareholder Information
| Metric | ALNY | BBIO |
|---|---|---|
| Shares Outstanding | 134M | 195M |
ALNY vs BBIO: stock comparison and AI forecast
Which is bigger, ALNY or BBIO?
ALNY is 1.5 times larger than BBIO by market capitalization ($21.42B against $14.42B).
Which one does Intratio's AI model rank higher, ALNY or BBIO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.